Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Horizon Awarded Funding Under Bio-Mfg. Initiative | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Horizon Awarded Funding Under Bio-Mfg. Initiative

Will receive as much as £652,000 to expand bioproduction research

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

A consortium led by the Centre for Process Innovation (CPI) on behalf of UCB Celltech, Lonza Biologics, and partner Horizon Discovery Group, have been awarded £6.2 million as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI).
 
The AMSCI program provides grant funding from the UK Government to support the future needs of biologics manufacturing in the UK. This initiative supports the development of next-generation production systems so that the most efficacious and cost-effective therapies are made available to patients.
 
Horizon will receive as much as £652,000 to expand bioproductionresearch. Horizon will use its gene editing and screening expertise to develop a high throughput platform to accelerate the development of novel and improved Chinese Hamster Ovary (CHO) cell lines, with the goal of allowing better decisions to be made on potential performance improvements for biologic drug manufacturing.
  
Dr. Paul Morrill, president, Products, Horizon Discovery Group, said, “Horizon, along with UCB and the other consortium partners, recognizes the importance of strengthening the biomanufacturing supply chain in order to deliver the next generation of biological medicines.  Enhancing cell line function through gene editing is a critical path activity towards this outcome. This initiative, alongside the recent Industrial Biotechnology Catalyst funding, further reinforces Horizon’s reputation as a driver of innovation for biomanufacturing.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics